Category

News
These man-made cancer-fighting molecules are infinitely variable, like a set of Legos, each one constructed to allow a patient’s immune cells to kill cancer cells. But, unlike selecting a red versus a blue block while building a colorful plastic tower, the consequences of your design choices when building what’s known as a CAR could have...
Continue Reading
CAR T-cell therapy, which reprograms immune cells to fight cancer, has shown great promise in people with some blood cancers who have not responded to other treatments. But until now, the underlying biological pathways enabling anti-cancer responses have not been thoroughly examined. Understanding these pathways is important for designing future generations of CAR T-cell therapies,...
Continue Reading
There are various treatment options for patients with multiple myeloma (MM), including autologous hematopoietic stem cell transplantation (HSCT), thalidomide, lenalidomide, bortezomib, and daratumumab. Each patient with MM is obviously not a candidate for all of these treatments, and each treatment plan needs to be tailored for the individual patient. A consistent challenge facing both health care...
Continue Reading
For 48-year old Atlanta mom, wife and dog groomer Cheri Letts, the realization she was sick came slowly. “I was starting to feel rundown, and it seemed like I had a cold that just wasn’t going away,” Letts says. She went to a series of health care practitioners, getting different diagnoses. But she was growing...
Continue Reading
There are currently 10 FDA-approved treatments in the multiple myeloma space; however, a more personalized therapy could be key to finding a cure, said Nikhil C. Munshi, MD. “In 5 years, we could be bold enough to say, ‘We have cured myeloma,’” said Munshi. “Combining all the drugs we have and combining what we know...
Continue Reading
Background: The refractory/relapsed multiple myeloma (RRMM) remains a big clinical challenge, due to its biological and clinical complexity. Leading hematologists have performed many randomized controlled trials (RCTs) worldwide, and their findings were summarized in a recently published network meta-analysis (NMA) but with certain limitations. Materials and methods: We performed an updated NMA of RCTs related to RRMM...
Continue Reading
To fight viral infections, your immune system calls on CD8 T cells to kill the infected cells. The CD8 T cells can also be used in immunotherapy approaches to kill cancer cells, including the CAR T cell therapy currently attracting broad public attention. “The problem is that CD8 T cells are often exhausted in cancer...
Continue Reading
While chimeric antigen receptor (CAR)-T cell therapy has demonstrated positive response rates in children with relapsed and/or refractory CD19-positive acute lymphoblastic leukemia (ALL), severe toxicities can also be associated with such treatment. So, a group of researchers issued guidelines to help ensure these patients experience optimal outcomes. “These guidelines are meant to be a truly...
Continue Reading
One of newest and most exciting approved treatments for cancer is the use of CAR-T therapy. CAR stands for chimeric antigen receptor and T stands for T-cell. Currently both Novartis (NVS) and Gilead (NASDAQ:GILD) have CAR-T therapies approved by the FDA. Axicabtagene (Yescarta) is sold by Gilead and is approved for refractory diffuse large b...
Continue Reading
The human immune system is truly a wonder. It plays a critical role in our body’s defense to invading disease. Like a home security system, it is on alert 24/7/365. Through multiple mechanisms, it guards all our tissues, protects us from microbial foreign invaders, and removes cancer cells to keep us disease-free. For example, B...
Continue Reading
1 28 29 30 31 32 37

Floor 7, 90 The Terrace
Wellington Central
New Zealand